Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron isomaltoside 1000 in Restless Legs Syndrome
NCT02484768Phase 2Withdrawn
- Sponsor
- Pharmacosmos
- Start
- Jan 2015
- Primary completion
- Feb 2015
- Modality
- Inorganic Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of ferric derisomaltose in restless legs syndrome (RLS), sponsored by Pharmacosmos. Planned start Jan 2015; status: withdrawn.
02
Drugs
ferric derisomaltose
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT02484768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484768.